Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholesterol drug reviews

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees will discuss the OTC switch potential of Merck's Mevacor (lovastatin) on July 13 and Bristol-Myers Squibb's Pravachol (pravastatin) on July 14, the agency confirms (1"The Tan Sheet" April 17, p. 3). The proposed OTC indication of both drugs is to "treat individuals with total cholesterol levels of 200-240 mg/dL and low density lipoprotein levels over 130 mg/dL," FDA reports. However, for Mevacor, the indication would apply to "men over 40 and postmenopausal women who do not have established cardiovascular disease or diabetes." Pravachol's proposed indication - "for individuals who do not have established cardiovascular disease or diabetes" - is not age- or gender-specific. A July 12 NDAC session also is scheduled, although a topic has yet to be announced. As a precursor to the advisory committee meeting, FDA is holding a public forum June 28-29 on the suitability of marketing certain Rx drug classes OTC (2"The Tan Sheet" May 1, p. 3)
Advertisement

Related Content

Rx-To-OTC Switch Flips On With June Public Forum, July NDAC Meeting
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

PS091177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel